You are here
Angiochem is a clinical-stage biotechnology company developing a new class of breakthrough drugs to treat brain diseases and brain-related disorders.
These highly innovative and efficacious pharmaceuticals are based on Angiochem’s proprietary EPiC Technology and have the potential to address significant medical needs, many of which have not be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.
With unique know-how of engineering methods and manufacturing processes, Angiochem is developing a deep and broad product pipeline for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others. These pharmaceuticals are composed of small molecules or biologics that are potent, proven, and designed to help improve the lives of patients.
Founded in 2003, Angiochem is backed by an experienced management team and board of directors, a robust scientific advisory board, and a dedicated group of investors. Angiochem maintains headquarters in Montreal, Canada.
Recognized for Innovation
Angiochem has been recognized for its leadership in advancing treatment for brain cancers with the recent Innovation Award presented by the U.S. National Brain Tumor Society. More >